Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Denosumab Therapy
NCT ID: NCT03702140
Last Updated: 2021-09-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
90 participants
INTERVENTIONAL
2018-10-09
2025-10-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. The administration period of teriparatide is less than 6 months and thereafter, denosumab for 24 months.
2. The administration period of teriparatide is from 6 to 12 months and thereafter, denosumab for 24 months.
3. The administration period of teriparatide is more than 12 months and thereafter, denosumab for 24 months.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
NCT02156960
A Study of Teriparatide in Japanese Osteoporosis Patients
NCT01430104
Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese
NCT02166437
The Forteo Alendronate Comparator Trial
NCT02416271
Effects of Teriparatide Therapy for Japanese
NCT01956461
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TPTD 6M
"Teriparatide", "Forteo® or Teribon"
To examine the effects of terimaratide less than 6 months in osteoporosis
TPTD 6-12M
"Teriparatide", "Forteo® or Teribon"
To examine the effects of terimaratide less than 6 months in osteoporosis
TPTD 12-24M
"Teriparatide", "Forteo® or Teribon"
To examine the effects of terimaratide less than 6 months in osteoporosis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
"Teriparatide", "Forteo® or Teribon"
To examine the effects of terimaratide less than 6 months in osteoporosis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
20 Years
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shinshu University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yukio Nakamura
Lecturer at Shinshu University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Yukio Nakamura
Matsumoto, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PTH-DMAb 2018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.